Resolian Appoints Rob Stachlewitz as CEO, Honggang Bi as Chairman of the Board, and Pat Bennett as Chief Business Officer and President of Scientific Affairs

Core Insights - Resolian is undergoing leadership changes to enhance its global operations and better support client needs [2][3] - The company has expanded its global footprint through strategic acquisitions and the establishment of new facilities [3][9] Leadership Changes - Rob Stachlewitz has been appointed as the new CEO, transitioning from his role at Charles River [5][6] - Pat Bennett, the former CEO, will take on the role of Chief Business Officer and President of Scientific Affairs [2][7] - Honggang Bi has been appointed as Chairman, bringing over 30 years of experience in drug development [4][6] Company Expansion - Resolian has made significant acquisitions, including Alliance Pharma, Drug Development Solutions, and Denali MedPharm, expanding its operations to four continents [3][9] - The establishment of a new bioanalytical lab in Brisbane, Australia, enhances its operational capabilities [3] Operational Focus - The leadership team aims to improve service capabilities and strengthen customer relationships [7][8] - The company employs nearly 500 experts across the U.S., U.K., and Australia, ensuring high standards of regulatory compliance [9]